Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Septic Shock
and you are
over 18
years old
The phase for this study is not defined.
Show me locations

The purpose

The main purpose at the early phase of septic shock on the evolution of organ failure judged by the SOFA (Sepsis Organ Failure Assessment score) score on Day 7 (or the day of death or the day of discharge from the intensive care unit if before Day 7) compared to SOFA score observed in patients in the control group. The secondary purpose is to assess the role of heterologous mesenchymal stem cells on the occurrence and duration of failure of each organ and on the mortality at day 28 and day 90. The safety of administration will be also assessed.

Provided treatments

  • Biological: Injection of mesenchymal stem cells
  • Biological: Injection of albumin alone
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02883803. The sponsor of the trial is Central Hospital, Nancy, France and it is looking for 66 volunteers for the current phase.
Official trial title:
Effects of Mesenchymal Stem Cells Administration on Organ Failure During Septic Shock: Phase II Randomized Comparator-controlled Study